Journal
PHYSIOLOGY
Volume 22, Issue -, Pages 81-96Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physiol.00037.2006
Keywords
-
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057263, R01HL083156, R01HL078691, R01HL071763, R29HL057263, R01HL080498] Funding Source: NIH RePORTER
- NHLBI NIH HHS [HL 071763, HL 080498, HL 083156, HL 057263, R01 HL 078691] Funding Source: Medline
Ask authors/readers for more resources
Heart failure is a major cause of morbidity and mortality in contemporary societies. Although progress in conventional treatment modalities is making steady and incremental gains to reduce this disease burden, there remains a need to explore new and potentially therapeutic approaches. Gene therapy, for example, was initially envisioned as a treatment strategy for inherited monogenic disorders. It is now apparent that gene therapy has broader potential that also includes acquired polygenic diseases, such as heart failure. Advances in the understanding of the molecular basis of conditions such as these, together with the evolution of increasingly efficient gene transfer technology, has placed congestive heart failure within reach of gene-based therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available